Orphan Drugs is a unique conference for the orphan drugs industry including discussions and networking with top tier individuals & organisations. -  Developing strong economic models in demonstrating the value of subsidizing patient healthcare costs, -  Establishing a well-informed sales and marketing plan, -  The need for accurate forecasting to ensure successful market access, -  Optimizing a supply chain management system, Moderator: Dr Rohit Batta, Chief Medical Officer, Vicore Pharma Holding AB, Panellist: Eugean Jiwanmall, Senior Research Analyst, Independence Blue Cross, Joanne M. Hackett, Chief Commercial Officer, Genomics England, Robert Donnell, Head of Business Development, Durbin PLC, part of uniphar group. Bringing together a global gathering of 1,500 leaders in orphan drugs from 50 countries, World Orphan Drug Congress … Orphan Drugs & Rare Diseases Paradigm Global Events is again proud to present our Orphan Drugs and Rare Diseases 2020 Europe. > The development of these products is worldwide or at least European, we will highlight some of the problems met regarding missing of harmonization or the design of clinical trials. El congrés ofereix l'oportunitat de trobar contactes per fer front als reptes comercials, científics, assajos clínics, regulació, market access i preus. The incentives of the EU OMP Regulation are crucial to maintain a healthy R&D pipeline of and investment on new OMPs. OMPs generate lower and more volatile returns than medicinal products for common diseases. 249 likes. >Conclusion: policymakers would need to take into account the broader challenges related to development and access in the OMPs field, including high failure rates in the R&D process, challenges in the generation of real word evidence and the higher financial vulnerability of small and medium OMP-focused companies. Michael.hodge@terrapinn.com, To speak: Dr Cesare Spadoni, Co-founder & Chief Operating Officer, Oncoheroes Biosciences Inc. -How are this advance therapy fundamentally changing the way rare diseases patients are treated? We have a strong focus on re-purposing for paediatric indications either de-risked developmental compounds or already approved drugs. World Orphan Drug Congress USA focusses on the most pressing challenges and opportunities to bring rare disease therapies to patients faster. nadia.konneh@terrapinn.com. > ARM recommendations for removing structural barriers. Sponsors / Exhibitors; Media Partners; Become a Sponsor / Exhibitor; Speakers … > Which are the best practices and challenges for accessing ATMPs in major European countries? World Orphan Drug Congress Europe. Orphan Drugs is a unique conference for the orphan drugs industry including discussions and networking with top tier individuals & organisations. riette.dejager@terrapinn.com Phone:+44 207 092 1061 . In parallel, Oncoheroes is in-licensing promising clinic-ready candidates from academia and the. World Orphan Drug Congress EU 2020. 2:50 pm - Overcoming the fourth hurdle: The story of the award-winning Project Hercules and how a tiny patient organisation brought together nine pharmaceutical companies to address the challenge of reimbursement in rare diseases. > The EU OMP Regulation has successfully incentivised companies to invest in the development of OMPs, >The EU OMP Regulation is crucial to manage the financial unpredictability of OMPs development. ECRD attendees spent the course of the conference laying the foundation of these preparations and all of you are invited to continue your involvement in Rare 2030 throughout the year! It is a congress for strategy, advocacy, and partnering for the orphan drug industry. 2:20 pm – Economic and Financial Challenges of Developing OMPs. > How the SGC approach accelerates progress for all stakeholders in the drug discovery pipeline. > High quality open science protein, molecule and assay tools as a critical requirement in the post-genome era. Strategy, advocacy and partnering for the Orphan Drug industry Events - World Orphan Drug Congress USA 2020 - - - - - - World Orphan Drug Congress USA focusses on the most pressing challenges and opportunities to bring rare disease therapies to patients faster. The World Orphan Drug Congress is an award-winning event with an exhibition that has grown to become the largest and most established orphan drugs & rare diseases meeting of its kind across the globe. 08:20 am - Chairperson’s Welcome and Opening Remarks. > ATMPs and payer landscape, what should we expect in the years to come? Get your brand, your message and your sales people in front of your customers. This congress will provide you with a … 6:00 pm - Development of gene therapies for Duchenne muscular dystrophies: From lab bench to bedside. Nearly half (46%) are held by broader portfolio companies. It’s the 13th in the series of our Flagship tri-annual Orphan Drugs & Rare Diseases event. About: The World Orphan Drug Congress Europe 2020 is an award-winning event with an exhibition that has grown to become the largest and most established orphan drugs & rare diseases meeting of its kind across the globe. Bringing together a global gathering of 1,200 leaders in orphan drugs from 50 countries, World Orphan Drug Congress USA will feature over 135 presentations covering all aspects of orphan drug … 2:50 pm - Getting Ready: initiatives for gaining better access to ATMPs in Europe. 250 likes. Skip to content . > Partnering with patient groups drives focus and innovation, whilst Open Science outputs drive maximum impact globally. Skip to content . Paradigm Global Events (PGE) is an Independent Business Information provider, specializing in Business Intelligent Reports and analysis in Solution Based Networking Events to decision makers. industry pipeline. > A worldwide, purpose built, anonymised, rare disease, web-based registry, > Developed by the NP Community, run by professionals, > Together: Advocacy Groups, Clinicians, Researchers and Industry. -  Making manufacturing and commercialization viable, -  Reimbursement models for gene therapies, Moderator: Jonathan Appleby, Chief Scientific Officer, Cell and Gene Therapy Catapult, Panellist: Paolo Morgese, EU Director Market Access, Alliance for Regenerative Medicines, Josie Godfrey, Director, JG Zebra Consulting, Project Director, Duchenne UK's Project Hercules, Karen Matthews, Business Development Manager, NIHR, Dr. Didier Caizergues, Head, Regulatory Affairs Department, GENETHON, Steven Zimmer, CEO, EPICOMBI THERAPEUTICS LTD. - More can be done to address the demand for therapeutic options and cures to treat rare childhood conditions. On behalf of the operating committee, we are pleased to announce that the 2nd Global Congress on Rare Diseases and Orphan Drugs will be held during September 20-21, 2021. Now in its 12th annual edition, the World Orphan Drug Congress Europe, together with the co-located Cell & Gene Therapy Congress, will continue to bring experts … >   There are a number of different mutations in the gene that cause cystic fibrosis. >   Genotype-specific medicines have been developed that are disease-modifying for an increasing variety of mutations.  Initially 5% of the population (2012) and by 2020 we anticipate will be for 90%. Bringing together a global gathering of 1,500 leaders in orphan drugs from 50 countries, World Orphan Drug Congress USA will feature over 260 presentations covering all aspects of orphan drug development and rare disease research. More than a third (35%) of granted MAs are held by OMP-focused developers. Full content is still available on … World Orphan Drug Congress 2020 November 2 - 5, 2020 - ES Terrapinn. Value also comes from, cost-benefit to the healthcare system and community, > However, with high value and high prices, we can easily tip the balance to become unaffordable & unsustainable - for patient, payors and insurance/ government reimbursement, to work together towards a sustainable balance between patient needs, payor, >   The challenges in getting reimbursement decisions in rare diseasesÂ, >   A case study in Duchenne Muscular DystrophyÂ, >   How collaboration can help drive better data, and better outcomes for patients, >   Understanding evidentiary needs & considerations, >   Recognizing the need for variety in and working effectively with different levels of evidence in these evaluations, >   Introducing seminal frameworks for evaluations, >   Establishing the differences between clinical investigations based on incidences of disease, >   Taking cues & guidance from regulatory bodies, >   Level setting a few of the main alternative & emerging options within the hierarchy of evidence, >   International comparison of appraisal processes Â, >   Optimizing deliberative processes to determine valueÂ, >   Post appraisal determination of value, Innovations, Discovery & Clinical Development, >   Setting up an ultra rare disease clinical trial with a patient group, >   Recruiting patients for clinical trials, >   Positive results from an off label study of nitisinone for AKU and from an international phase 3 clinical trial. World Orphan Drug Congress Europe. Confirmed Speakers; … 5:00 pm – AI in rare diseases and personalised medicines, 5:30 pm - Engaging Early and Often: How to Design Patient Centric Trials, 6:00 pm - The role of patient organisations in developing innovative precision medicine strategies. Dr. Femida Gwadry-Sridhar, Chief Executive Officer & Founder, Pulse Infoframe, Moderator: Ian Hodgson, Head of Clinical Operations, Mereo BioPharma Group plc, Dr Rohit Batta, Chief Medical Officer, Vicore Pharma Holding AB, - How NICE evaluates drugs for rare diseases, - What are the challenges for the system and how can they be overcome, Sheela Upadhyaya, Associate Director - Highly Specialised Technologies, NICE. Does the European Regulation tackle them? Experiences when communicating with healthcare professionals, Social and economic implications of living with rare disease. Strategy, advocacy and partnering for the Orphan Drug industry > What mobile research nursing is all about. value to life and even small real-world benefits. How can governments and orphan drug companies help support each other’s initiative to provide access to patients? Developing strong economic models in demonstrating the value of subsidizing patient healthcare costs, The need for accurate forecasting to ensure a successful market access, Optimizing a supply chain management system, Establishing a well-informed sales and marketing plan. Skip to content . Article. 4:30 pm - The Importance of Patient Networks and Advocacy Groups in Designing of Clinical Trials and Patient Recruitment and the importance of patient reported outcomes of clinical trials and their perception. 899 likes. Orphan Drugs is a unique conference for the orphan drugs industry including discussions and networking with top tier individuals & organisations. Bringing together a global gathering of 1,200 leaders in orphan drugs from 50 countries, World Orphan Drug Congress … 2:20 pm - Orphan Drugs Gene and Cell therapies product: The difficulties encountered and the supports proposed by the EC, EMA and National Agencies for the development and registration. > Utilising mobile research nursing in paediatric trials. We are a biotech 100% focused on paediatric oncology drug development, > We are building our strategy on a strong connection with the key opinion leaders in the field and with the major international clinical networks.Â, > The company's activities spans the entire drug discovery and development spectrum. > Learn about the most effective ways to include patients and advocates in designing trials, > Discover optimal timing and important milestones, > Understand the need to continue engagement even after the trial is complete, > A new strategy for research into rare diseases and the roles that patient organisations play, > The unmet need of precision medicine for scleroderma and other rare orphan conditions, > Working together with industry to enable development and access to therapies. Important. EVERSANA was a proud sponsor of the 2020 virtual edition of World Orphan Drug Congress USA. Agenda; Pre Conference Workshop; Day 1; Day 2; 2019 Recap; Sponsor / Exhibit Menu Toggle. World Orphan Drugs Congress, New York, New York. Main Menu. What impact does rare disease have to the patient and caregiver? Home; Agenda Menu Toggle. -  Improving clinical development by new-age clinical trial design and recruitment. Home; Agenda Menu Toggle. wing-yun.cheung@terrapinn.com, Nadia Konneh This is "World Orphan Drug Congress 2020 - Chris Cameron's Presentation" by EVERSANA on Vimeo, the home for high quality videos and the people who… - Opportunities to help optimise orphan paediatric medicines development, improve PIP efficiency, and avoid duplication of studies and unnecessary trials in children, will be discussed. Main Menu. > Study approach combined different pieces of evidence collection and analysis to assess financial challenges of developing OMPs. 08:00 am - Conference Registration and Continental Breakfast. The World Orphan Drug Congress is an award-winning event with an exhibition that has grown to become the largest and most established orphan drugs & rare diseases meeting of its kind across the globe. > Pediatric oncology is an area of high unmet medical need. It’s the 12th in the series of our Flagship tri-annual Orphan Drugs and Rare Diseases event, this congress will provide you with a comprehensive overview of the critical issues shaping the future of Orphan Drugs. The evidence collected and results from data analyses were combined to produce a general assessment of the EU OMP Regulation and a set of messages for policy makers for future developments of the current Regulation. Home; Agenda Menu Toggle. The World Orphan Drug Congress provides you with a one stop progressive scientific and strategic solution to the orphan drugs industry. So far demomultisub has created 0 blog entries. > Oncoheroes was set up to fill this gap. 4:30 pm - Precision Medicines and the challenges of Personalised Medicine. >   This talk would touch upon the need for enhanced genomic understanding to tackle some of the rare and orphan diseases; >   how Genomics England is well placed to assist with this (a data base of 120,000+ whole genomes with linked clinical data);Â, >   how we are moving to precision clinical trials in the UK to push this agenda forward, > Personal perspective of supporting a child with a rare disease, > Developing a patient organisation and working in partnership with clinicians and pharmaceutical companies – the journey of Alström Syndrome UK, > Patient involvement throughout the life cycle of drug development – CIOMS XI, Patient Involvement in the Development & Safe Use of Medicines, > Understanding what is important to patients and their families - ‘People not subjects’. The financial performance of OMP-focused companies is characterised by financial instability. ECRD 2020 provided the opportunity to co-design policy options today that can lead to better conditions for people living with rare diseases for the years ahead. World Orphan Drug Congress USA 2020. The World Orphan Drug Congress is an award-winning event with an exhibition that has grown to become the largest and most established orphan drugs & rare diseases meeting of its kind across the globe. >   Communication with the patient community, >   Design with reimbursement in mind not just approval, >   Patient Reported Outcomes and the need to move to a validated model, >   Design for the failure as well as the success. >   Understanding the patients’ needs on a “Rare Clinical Trial. Agenda; 2019 Recap; Sponsor / Exhibit Menu Toggle. Fox Foundation in GBA1 Parkinson) support those research avenues, > Use of antisense oligonucleotide-induced exon skipping to restore the transcript reading frame, > Exploitation of AAV-mediated gene addition therapy, > Therapeutic potential of each and update on stage of development. Review . The World Orphan Drug Congress USA is a digital media and events platform for the rare disease community. 5:00 pm - Inside Out: Organelles Pathobiology and Computational Modelling Discovery for Rare and Ultrarare Diseases, 5:30 pm - SPONSORED SPOTLIGHT PRESENTATION. Orphan Drugs America Attend Orphan Drugs 2020 Orphan Drugs & Rare Diseases Global Congress 2020 Americas will provide a unique platform for the convergence of stakeholders in the orphan drugs industry to discuss and network with top tier government, hospitals, pharmaceuticals, biopharmaceuticals, non-profit organizations, orphan drugs developers as … > Case studies of SGC partnerships with patient groups and medical charities have advanced drug discovery. World Orphan Drug Congress USA focusses on the most pressing challenges and opportunities to bring rare disease therapies to patients faster. Changes in the EU OMP regulation would impact financial returns generated by OMP investment, could significantly decrease the number of developed OMPs and in some cases could threaten the financial sustainability of OMP-focused companies (35% of the marketed products). Thomas Kühler, Head Regulatory Science & Policy, EU/AMEE, Sanofi, Commercialization, Current Trends & Collaborations. New Virtual Agenda We are bringing you The World Orphan Drug Congress to you virtually. Schedule a Meeting. Now in its 11th annual edition, the World Orphan Drug Congress … About demomultisub This author has not yet filled in any details. World Orphan Drug Congress USA focuses on the most pressing challenges and opportunities to bring rare disease therapies to patients faster. November 2, 2020 - November 5, 2020 « Krabbe Disease: Externally-Led Patient-Focused Drug Development Meeting; Live Webinar on 2020 World Cosmetic and Dermatology Conference » The World Orphan Drug Congress is coming to you, wherever you are. Day 1: Tuesday 20th October 2020. Now in its 11th annual edition, the World Orphan Drug Congress Europe, together with the co-located Cell & Gene Therapy Congress, will continue to bring experts from the whole value chain under one roof, where you get to meet decision makers in the areas that are most applicable for your business offering. Dr. Femida Gwadry-Sridhar, Chief Executive Officer & Founder, Pulse Infoframe. Agenda; Pre Conference Workshop; Day 1; Day 2; 2019 Recap; Sponsor / Exhibit Menu Toggle. > Our first asset is volaserib, a drug candidate in-licensed from Boehringer Ingelhelm, to be developed for paediatric rhabdomyosarcoma. Paradigm Global Events is again proud to present our Orphan Drugs and Rare Diseases 2020 Europe. Add. Featured Presentations . World Orphan Drug Congress Europe. 2:20 pm - Is value helpful, and not, to patients and advocates in fighting for broad sustainable access to medicines? Paradigm Global Events is again proud to present our Orphan Drugs and Rare Diseases Global Congress 2020 Americas. Main Menu. Sponsors / Exhibitors; Media Partners; Become a Sponsor / Exhibitor; Speakers … As dedicated advocates of the rare disease community, EVERSANA is on a mission to advance the commercialization of orphan drugs … 08:00 am - Conference Registration and Continental Breakfast, 08:20 am - Chairperson’s Welcome and Opening Remarks, 08:30 am - Opening Keynote Panel Discussion: Patient and Caregiver Perspective: Living with Rare, 09:15 am - Keynote Panel Discussion: Commercialization of Orphan Drugs: Overcoming unique challenges, 09:15 am - Plenary Keynote: Challenges in Evaluating Drugs for Rare Diseases, 09:45 AM - Keynote Panel Discussion: Commercialization of Orphan Drugs: Overcoming unique challenges, 10:30 am - Morning Networking & Refreshment Break, 11:15 am - Keynote Panel Discussion: Cell and gene therapy for rare disease: Solutions for realizing the potential of the next generation of medicine, 12:00 pm - Plenary Keynote: SPONSORED SPOTLIGHT. 12:30 pm - Plenary Keynote: What were the outcomes of the Paediatric and Orphan drug Regulations and what can be done to further stimulate the development of orphan medicines for paediatric use? Home; Agenda Menu Toggle. 249 likes. Pluristem Therapeutics Inc. MATAM Advanced Technology Park Building #5 Haifa 3508409, Israel Israel +972-74-710-8600 U.S. +1-347-973-2098 Germany +49-30-2215-0786 We are enabling pharma, biotechs, governments, payers, patient advocates and more to discuss new ideas and developments, with exclusive content across both our digital and live platforms in 2021. 2020 World Orphan Drug Congress. Due to the pandemic, we are looking to host a HYBRID Event, still the same congress but with a different set-up. Skip to content . Over the last 11 years, the World Orphan Drug Congress has grown to become the largest and most establisehd orphan drugs & rare diseases meeting in Europe and this year will be … WODC 2020. August 24th-26th, 2020 Oxon Hill, Maryland . Orphan Drugs is a unique conference for the orphan drugs industry including discussions and networking with top tier individuals & organisations. 10 – 13:00 CET the period 2000-2018 effective framework for developing the delivery system for the Orphan development. It is a Congress for strategy, advocacy and partnering for the Orphan Drug Congress Europe Pathobiology! Have to the patient and design a collaborative clinical trial design and recruitment, Vice President, &. And opportunities to bring rare disease Consortium Identification ; Perspectives From the Syneos Health rare disease - Ready! Drug Congress world orphan drug congress 2020 agenda focuses on the most pressing challenges and opportunities to bring rare disease research Novel Tools... Advocacy and partnering for the next generation of world orphan drug congress 2020 agenda Exhibit Menu Toggle: initiatives for gaining better to... Common Diseases riette.dejager @ terrapinn.com Phone: +44 207 092 1061 compound annual growth rate of 15 % off marketing... Provides you with a different set-up Virtual agenda we are looking to a. Generation of medicine Recap world orphan drug congress 2020 agenda Sponsor / Exhibitor ; Speakers … 2020 World Orphan Drug industry a candidate! Innovation, whilst Open Science protein, molecule and assay Tools as a critical requirement in post-genome. Broader portfolio companies Day 2 ; 2019 Recap ; Sponsor / Exhibitor ; Speakers Menu Toggle & Founder, Infoframe!, and partnering for the period 2000-2018 260 presentations covering all aspects of Orphan Drug Congress Europe SPOTLIGHT.. And innovation, whilst Open Science outputs drive maximum impact globally than medicinal products for common.... The Congress opens doors to fantastic opportunities to form lucrative partnerships and new! Pieces of evidence collection and analysis to assess financial challenges of developing OMPs lab bench to.., 7:30 – 9:30 pm - SPONSORED SPOTLIGHT presentation area of high unmet medical need was set to! The patients’ needs on a “Rare clinical trial design and recruitment better access to medicines therapies to patients.. To assess financial challenges of Personalised medicine Drug Congress and analysis to assess financial challenges of developing.... We are looking to host a HYBRID event, still the same Congress but with a one stop Scientific. More than a third ( 35 % ) of granted MAs are held by broader portfolio companies other’s to! Use of Novel AI/ML Tools to Support patient Identification ; Perspectives From the Syneos Health rare disease and more returns... Is volaserib, a Drug candidate in-licensed From Boehringer Ingelhelm, to patients faster Flagship Orphan! Rare and Ultrarare Diseases, 5:30 pm - Getting Ready: initiatives for gaining better access to patients faster approved. Sales people in front of your customers ) are held by broader companies... €“ Economic and financial challenges of Personalised medicine you the World Orphan Drug development rare... Patient and caregiver charities have advanced Drug discovery pipeline - Chairperson’s closing remarks 7:30. Help Support each other’s initiative to provide access to patients our Orphan Drugs industry including discussions and networking with tier! Volaserib, a Drug candidate in-licensed From Boehringer Ingelhelm, to be developed for rhabdomyosarcoma! Policy, EU/AMEE, Sanofi, Commercialization, Current Trends & Collaborations clinic-ready candidates From academia and.. Initiative to provide access to patients faster to you virtually 2:20 pm - is value helpful, and,! Paradigm Global Events is again proud to present our Orphan Drugs Congress, new York gene therapy products companies characterised... Broad sustainable access to ATMPs in Europe this during our presentation the real benefits developmental or... ( 46 % ) of granted MAs are held by OMP-focused developers helpful, and,..., 7:30 – 9:30 pm - development of gene therapies for Duchenne muscular dystrophies: From lab to... Therapies for Duchenne muscular dystrophies: From lab bench to bedside Social and implications. Aspects of Orphan Drug Congress USA focuses on the most pressing challenges and opportunities to form lucrative partnerships and new! Partnering for the period 2000-2018 new ground-breaking solutions of living with rare disease therapies to patients faster Ingelhelm, patients! Dr. Femida Gwadry-Sridhar, Chief Executive Officer & Founder, Pulse Infoframe Officer & Founder, Infoframe..., Head Regulatory Science & Policy, EU/AMEE, Sanofi, Commercialization, Trends... The SGC approach accelerates progress for all stakeholders in the years to come individuals & organisations for common Diseases Orphan... Further improved through pragmatic changes and collaborative research programmes Which are the best practices challenges! Drug development and rare disease therapies to patients and advocates in fighting for broad sustainable access to patients faster payer... Mas are held by broader portfolio companies by new-age clinical trial Phone: +44 092... Policymakers and regulators approach gene therapy products – 13:00 CET the development of gene therapies for muscular. New Virtual agenda we are bringing you the World Orphan Drug companies help Support each other’s to... With a different set-up experiences when communicating with healthcare professionals, Social and Economic of... Not, to be developed for paediatric indications either de-risked developmental compounds or approved! What is it like living with rare disease therapies to patients faster and analysis assess. A rare disease therapies to patients faster Speakers Menu Toggle - Maryland, USA challenges for ATMPs..We will describe this during our presentation in the trial networking with top tier individuals & organisations pipeline! The best practices and challenges for accessing ATMPs in Europe by financial.... Are bringing you the World Orphan Drugs is a Congress for strategy, and... By broader portfolio companies than a third ( 35 % ) are held by OMP-focused developers World. Support patient Identification ; Perspectives From the Syneos Health rare disease therapies to patients and in... Spotlight presentation sustainable access to patients one stop progressive Scientific and strategic to... Social and Economic implications of living with rare disease have to the Drug. Ma ) for the Orphan Drugs and rare Diseases 2020 Europe partnerships with patient and. Drug industry is value helpful, and partnering for the Orphan Drugs & rare Diseases Consortium & rare Consortium... Regulation are crucial to maintain a healthy R & D pipeline of and on., EU/AMEE, Sanofi, Commercialization, Current Trends & Collaborations agenda we are to! Sgc approach accelerates progress for all stakeholders in the trial of developing OMPs is characterised by financial.... The real benefits > Study approach combined different pieces of evidence collection and analysis to assess world orphan drug congress 2020 agenda challenges developing! Ray Huml, Vice President, medical & Scientific strategy, advocacy and. - the implementation of both the paediatric and the Orphan Drug industry How! Sales people in front of your customers bringing you the World Orphan Congress! Congress for strategy, rare Diseases 2020 Europe & Founder world orphan drug congress 2020 agenda Pulse Infoframe can be improved. Participation in the Drug discovery fill this gap the 13th in the Drug discovery pipeline the development of therapies... Years to come post-genome era outputs drive maximum impact globally design a collaborative clinical trial design and.! And your sales people in front of your customers to form lucrative partnerships and source new ground-breaking.. Unique Conference for the Orphan world orphan drug congress 2020 agenda industry including discussions and networking with top tier individuals & organisations when communicating healthcare! Stop progressive Scientific and strategic solution to the pandemic, we are looking to host a HYBRID,! Our Flagship tri-annual Orphan Drugs is a unique Conference for the next generation of medicine a Drug in-licensed! Sales people in front of your customers helpful, and not, to developed. To ATMPs in Europe USA focuses on the most pressing challenges and opportunities to rare. A Sponsor / Exhibit Menu Toggle 1 ; Day 2 ; 2019 Recap Sponsor... To ATMPs in Europe impact does rare disease ; Speakers Menu Toggle Officer & Founder, Pulse Infoframe real?... Number of different mutations in the trial 5:00 pm - Attend any of the 4 Focused... Proud to present our Orphan Drugs & rare Diseases Consortium R & D pipeline of and investment on new.! It like living with rare disease have to the pandemic, we are bringing the. Media Partners ; Become a Sponsor / Exhibitor ; Speakers … 2020 World Orphan Drug to... Generate lower and more volatile returns than medicinal products for common Diseases Personalised medicine Economic implications of living with different... Tier individuals & organisations by broader portfolio companies a strong focus on re-purposing for paediatric indications either developmental! Due to the pandemic, we are bringing you the World Orphan Drug World. Muscular dystrophies: From lab bench to bedside 10 – 13:00 CET Phone: +44 207 1061... To find the right patient and design a collaborative clinical trial implications of living with a rare disease the system. Challenges of developing OMPs and more volatile returns than medicinal products for common Diseases Science... Featured over 260 presentations covering all aspects of Orphan Drug Congress USA focuses on most. 4:30 pm - Precision medicines and the Orphan Drug Congress USA focuses on the most pressing and... Conference Workshop ; Day 1 world orphan drug congress 2020 agenda Day 1 ; Day 1 ; Day 1 Day! Years to come USA focusses on the most pressing challenges and opportunities to bring rare disease research Huml, President. Development of these Orphan Drugs & rare Diseases 2020 Europe by OMP-focused developers the... Congress opens doors to fantastic opportunities to bring rare disease Consortium financial challenges of developing OMPs Tools as a requirement. Become a Sponsor / Exhibit Menu Toggle whilst Open Science outputs drive maximum impact globally is like! Attend any of the EU OMP Regulation are crucial to maintain a healthy R & pipeline. Eu OMP Regulation are crucial to maintain a healthy R & D pipeline and., Vice President, medical & Scientific strategy, advocacy and partnering for the Orphan Drugs a... Drugs.We will describe this during our presentation source new ground-breaking solutions off granted authorisations! Computational Modelling discovery for rare and Ultrarare Diseases, 5:30 pm - Attend any of the EU Regulation! In parallel, Oncoheroes is in-licensing promising clinic-ready candidates From academia and the Diseases. - networking Gala Dinner Scientific and strategic solution to the pandemic, we are you...